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Background: Maintenance of a well-functioning vascular access and minimal
needling pain are important goals for achieving adequate dialysis and improving the
quality of life in hemodialysis (HD) patients. Far-infrared (FIR) therapy may improve
endothelial function and increase access blood ﬂow (Qa) and patency in HD pa-
tients. The aim of this study was to evaluate effects of FIR therapy on Qa and
patency, and needling pain in HD patients.
Methods: This prospective clinical trial enrolled 25 outpatients who maintained HD
with arteriovenous ﬁstula. The other 25 patients were matched as control with age,
sex, and diabetes. FIR therapy was administered for 40 minutes during HD 3 times/
wk and continued for 12 months. The Qa was measured by the ultrasound dilution
method, whereas pain was measured by a numeric rating scale at baseline, then
once per month.
Results: One patient was transferred to another facility, and 7 patients stopped FIR
therapy because of an increased body temperature and discomfort. FIR therapy
improved the needling pain score from 4 to 2 after 1 year. FIR therapy increased the
Qa by 3 months and maintained this change until 1 year, whereas control patients
showed the decrease in Qa. The 1-year unassisted patency with FIR therapy was not
signiﬁcantly different from control.
Conclusion: FIR therapy improved needling pain. Although FIR therapy improved
Qa, the unassisted patency was not different compared with the control. A larger
and multicenter study is needed to evaluate the effect of FIR therapy.
Copyright © 2016. The Korean Society of Nephrology. Published by Elsevier. This is
an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Awell-functioning vascular access site and relief of needling
pain are important factors for achieving adequate dialysis andternal Medicine, Soon-
0 Jomaru-ro, Jung-dong,
.
ty of Nephrology. Published b
/4.0/).improving the quality of life in hemodialysis (HD) patients.
Although many surveillance methods have been developed to
detect early vascular access dysfunction in patients with arte-
riovenous ﬁstulas (AVFs), surveillance has not been shown to
improve access survival in the grafts [1]. Thus, many re-
searchers have tried to improve vascular access survival with
medications and other techniques.
Far-infrared (FIR) radiation comprises electromagnetic
waves with wavelengths that range from 5.6 to 1,000.0 mm.y Elsevier. This is an open access article under the CC BY-NC-ND license
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thermoreceptors in the surrounding skin [2]. FIR therapy im-
proves skinbloodﬂow[3]. FIR therapyalso improves endothelial
function and reduces the frequency of some cardiovascular
diseases [4e6]. Vascular access dysfunction is a major problem
in HD patients. FIR radiation is a novel therapy that reported to
improve the unassisted patency at 1 year in the patients with
AVF population [7]. Lin et al [8] reported that FIR therapy im-
proves the blood ﬂow, maturation, and patency of a newly
created AVF in patients with stage 4e5 chronic kidney disease.
The aim of the present study was to evaluate the effects of FIR
therapy on vascular access blood ﬂow (Qa) and needling pain in
HD patients.
Methods
Study design
This was a prospective clinical trial conducted from June
2013 to July 2014 at Soonchunhyang University Bucheon Hos-
pital. All enrolled patients were maintained with 4 hours of HD
3 times/wk in our clinic. Eligible patients were thosewho either
had no history of percutaneous transluminal angioplasty (PTA)
or had undergone 1 PTA procedures, with the last PTA pro-
cedure successfully performed within 1 week before enroll-
ment. We excluded patients who underwent HD treatment at a
frequency other than 3 times/wk, had previously undergone
FIR radiation therapy, had missed more than 10% of FIR treat-
ments, had a history of kidney transplantation, were switched
to peritoneal dialysis, or had severe disease with an estimated
life expectancy of < 1 year. Data relevant to baseline charac-
teristics [age, sex, HD therapy duration, PTA history, presence or
absence of diabetes mellitus (DM), hypertension, liver disease,
coronary artery disease, cerebrovascular disease, peripheral
arterial disease, and medications] and patency outcomes were
observed.
Patients provided written informed consent before begin-
ning the study. The study was conducted in accordance with
the Declaration of Helsinki and was approved by the Soon-
chunhyang University Bucheon Hospital Institutional Research
Board.
FIR radiation therapy
FIR therapy was performed for 40 minutes during each HD
session.We started FIR therapywithin 30minutes after starting
HD. Specialized FIR emitters (WS TY-101N; WS Far Infrared
Medical Technology Co., Ltd., Taipei, Taiwan) were used for FIR
therapy. Electriﬁed ceramic plates were positioned approxi-
mately 25 cm above the skin surface at the needling site. The
irradiating power density was about 10 and 20 mW/cm2 when
the radiator was set at a distance of 30 and 20 cm above the
skin surface, respectively. Radiation therapy was continued in
every HD session.
Measurement of Qa and pain
Qa was monthly measured within 2 hours after start of HD.
Measurement was performed by the ultrasound dilution
method using a Transonic HD03 HD monitor (Transonic Sys-
tems, Ithaca, NY, USA) [9]. Qa was measured before and after
intervention in patients with FIR therapy. Needling pain andanxiety in patients were measured with a numeric rating scale.
The scale indicated pain severity on a scale of 0e10 points,
which correlated with no pain and uncontrolled severe pain,
respectively.
The mean baseline Qa and pain were obtained during the 1
week before the start of the study. These parameters were then
recorded at months 1, 3, 6, and 12 after beginning the study.
Study protocol
Effect of FIR therapy in a single HD session
We measured the study participants' Qa, body temperature
(BT), and pain and anxiety scores before and after FIR therapy.
The patients scored their own pain and anxiety. The nurse
checked the patients' skin status in terms of inﬂammation,
burning, or other abnormalities; sense of itching before
needling; bleeding site during HD; and time required for
hemostasis.
Effect of 1 year of FIR therapy on Qa and unassisted patency
We measured the study participants' Qa, BT, and pain and
anxiety scores before and at months 1, 3, 6, and 12 after the
start of the study. The primary outcome was the unassisted
patency, which was deﬁned as the time from study
commencement to the ﬁrst episode of AVF malfunction. We
deﬁned AVF malfunction as the need for any interventional
procedure (surgery or angioplasty) to correct an occlusive or
malfunctioning AVF that could not sustain an extracorporeal
blood ﬂow of > 200 mL/min during HD.
To analyze the effect of Qa and unassisted patency, we
compared the study participants who underwent 1 year of FIR
therapy with control patients who received no intervention for
their access site during the study period. We matched the
controls and participants by age, sex, and presence of DM.
Statistical analysis
Statistical differences in clinical characteristics and Qa per
month between the 2 groups were evaluated using the c2 test
or Fisher's exact test for categorical variables and Student's t
test or the Wilcoxon rank-sum test for numerical variables.
Univariate andmultivariate Cox proportional hazard regression
analyses were conducted to determine the predictors of unas-
sisted patency survival. The survival probability of unassisted
patencywas estimated according to the KaplaneMeier method,
and survival curves were compared with the log-rank test. The
Wilcoxon signed-rank test was used to compare differences in
Qa between pre- and post-FIR therapy. All statistical analyses
were performed using SAS software (version 9.4 for Windows;
SAS Institute, Inc., Cary, NC, USA). The statistical signiﬁcance
level was set at P < 0.05 (2-tailed).
Results
Twenty-ﬁve HD patients (mean age, 52.6 ± 10.7 years; 40%
female) were enrolled in FIR therapy and other 25 HD patients
were matched as control after the study. Table 1 compares the
baseline characteristics between the FIR therapy group and
control group. The clinical baseline characteristics were similar
in both goups with the exception of treatment with calcium
channel blockers and anticoagulation agents.
Table 1. Clinical characteristics of study populations
Variable FIR therapy (n ¼ 25) Control (n ¼ 25) Comparison (P)
Age (y) 52.6 ± 10.7 54.0 ± 11.0 0.648
Male 10 (40) 13 (52) 0.570
Comorbid disease
DM 13 (52) 10 (40) 0.570
Hypertension 21 (84) 24 (96) 0.359
Cardiovascular disease 7 (28) 6 (24) 1.000
Cerebrovascular disease 3 (12) 3 (12) 1.000
Peripheral vascular disease 3 (12) 3 (12) 1.000
Liver disease 4 (16) 0 (0) 0.118
HD vintage (mo) 68.3 ± 62.4 42.5 ± 47.7 0.108
Previous PTA Hx 10 (40) 8 (32) 0.769
Medications
Calcuim channel blockers 17 (68) 9 (36) 0.048
Beta blocker 12 (48) 6 (24) 0.141
Alpha blocker 2 (8) 1 (4) 1.000
RAS blocker 11 (44) 5 (20) 0.130
Anticoagulation drug 17 (68) 9 (36) 0.048
Access ﬂow (mL/min) 881.6 ± 748.4 1,024.4 ± 486.3 0.428
Thrombosis 2 (8) 7 (28) 0.138
Data are presented as mean ± SD or number (%).
P values were calculated by chi-square test, Fisher's exact test, and 2-sample t test.
DM, diabetes mellitus; FIR, far-infrared; HD, hemodialysis; Hx, history; PTA, percutaneous transluminal angioplasty; RAS, Renin angiotensin system.
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(28%) refused to continue the FIR therapy. In total, 17 patients
completed 1 year of FIR therapy. The follow-up duration was
9.8 ± 3.8 months. Thrombosis occurred in 2 patients at 0.5 and
5 months, respectively.
Effect of a single session of FIR therapy
We analyzed all FIR sessions of all participants to evaluate a
single session of FIR therapy. The total number of sessions was
107. There was no signiﬁcant difference in Qa, systolic blood
pressure (BP), or diastolic BP before and after a single session of
FIR therapy. The median BT increased from 36.6C to 37.2C
after FIR therapy (P < 0.001; Table 2).
No patient experienced a burn episode during FIR therapy.
Six patients complained itching sensations in 28 sessions. FIR
therapy improved itching sensation in 11 sessions of them.
Access site bleeding and delayed hemostasis at the needling
sites after FIR therapy were seen in 3 and 19 sessions,
respectively.
Effect of 1 year of FIR therapy
One and 6 patients stopped the FIR after 2 and 5 months,
respectively, because of a high BT and discomfort. However, FIR
therapy improved the needling pain scores from 4 to 2Table 2. Effects of FIR therapy on access blood ﬂow, body tempera-
ture and blood pressure
Variable Before FIR After FIR Comparison
(P)
Mean ± SD Mean ± SD
Access ﬂow (mL/min) 963.9 ± 721.1 997.4 ± 791.4 0.281
Body temperature (C) 36.6 ± 0.4 37.2 ± 0.6 < 0.001
Systolic blood
pressure (mmHg)
136.9 ± 24.6 134.8 ± 26.2 0.413
Diastolic blood
pressure (mmHg)
67.8 ± 15.4 67.9 ± 15.2 0.878
Data are presented as mean ± SD.
P values were calculated by 2-sample t test.
FIR, far-infrared.(Table 3). The Qa of FIR therapy increased from 881.6 to
934.7 mL/min (P ¼ 0.788). However, there was no statistical
signiﬁcance.Effect of FIR therapy on Qa and survival
We compared the 1-year change in Qa between the study
participants and control patients (Table 4). Because baseline Qa
between the 2 groups was slightly different, we compared the
change of Qa during follow-up months from baseline (Fig. 1).
The change of Qa in patients with FIR therapy was increased by
3months andmaintained this change until 1 year, whereas that
in controls was decreased. The 1-year unassisted patency rate
of FIR therapy was not signiﬁcantly different from that of
controls (Fig. 2).
Next, we analyzed the risk factors for the 1-year change of
Qa (Table 5) and unassisted patency rate (Table 6). FIR therapy
did not signiﬁcantly inﬂuence the 1-year change of Qa in uni-
variate analysis. Low initial blood ﬂow ratewas relatedwith the
1-year change of Qa. The overall unassisted patency was ﬁtted
to a Cox proportional hazard regression model including age,
sex, DM, hypertension, initial Qa, and FIR therapy in univariate
and multivariate analyses. DM (hazard ratio, 5.61; P ¼ 0.042)
was only related with the 1-year unassisted patency in the
multivariate Cox regression analysis.Table 3. Effect of FIR therapy on needling pain
Variable FIR therapy P
n ¼ 25
Pain, median (IQR) 0.002
At baseline 4 (2e7)
At 1 mo 1 (1e1)
At 3 mo 1 (1e1)
At 6 mo 1 (1e4)
At 12 mo 2 (1e4)
P value was computed by repeated-measures ANOVA at each time.
ANOVA, analysis of variance; FIR, far-infrared; IQR, interquartile range.
Table 4. Effects of FIR therapy on access blood ﬂow and unassisted
ﬁstula patency
Variable FIR therapy
(n ¼ 25)
Control
(n ¼ 25)
Comparison
(P)
Access ﬂow(mL/min)
At baseline 881.6 ± 748.4 1,024.4 ± 486.3 0.428
At 1 mo 944.4 ± 745.0 900.4 ± 327.1 0.789
At 3 mo 1,013.4 ± 854.0 938.8 ± 420.0 0.702
At 6 mo 931.8 ± 691.0 898.8 ± 409.0 0.847
At 12 mo 934.7 ± 525.0 980.0 ± 491.7 0.777
Data are presented as mean ± SD.
P values were calculated by 2-sample t test for access ﬂow and chi-
square test or Fisher's exact test for unassisted patency.
FIR, far-infrared.
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Patients on HD have numerous medical, social, and eco-
nomic problems [10]. HD patients have a lower quality of life
and more stress than patients with chronic kidney disease
without dialysis [11]. Fear of needling and pain are major bar-
riers to HD [12]. The buttonhole technique and topical anes-
thetic agents have been applied to vascular access to decrease
needling pain [13,14]. In the present study, FIR therapy
decreased the needling pain score from 4 to 2 during 12months
(Table 3). This is similar to our previous study, which showed
that the buttonhole technique decreased the needling pain
score [15].
Our results also evaluated the safety of FIR therapy. Of the 25
patients, 17 (68%) continued FIR therapy. Our patients dis-
continued the intervention more frequently than in other re-
ports (3.4e12.5%) [7,8]. Although others [7,16] reported no
complications associated with FIR therapy, side effects such as
an itching sensation and delayed hemostasis were seen in the
present study. This result is in line with the previous report of
Lin et al [17].Figure 1. Comparison of change in Qa between FIR therapy group and cont
*P < 0.05, **P < 0.01 vs. control.
FIR, far-infrared; Qa, access blood ﬂow.A single session of FIR increased the BT and tended to in-
crease Qa and decrease systolic pressure (Table 2). Lin et al [7]
did not observe on BT or BP but reported a signiﬁcant incre-
mental change in access ﬂow with a single session of FIR
therapy.
Fig. 1 showed that the FIR therapy increases Qa by 3 months
and maintained until 1 year, whereas control patients had the
decrease of Qa. This trend was revealed in a previous study, in
which Lin et al [17] showed that FIR therapy improves access
ﬂowandmaturation of newly created AVFs. Mean HD vintage of
our patients was 68.3 months. In other words, FIR therapy can
improve Qa in old access.
Although non-DM patients had the greater change of Qa in
FIR therapy compared with DM patients, those with initial Qa
< 500 mL/min had the greater change compared with those
with initial Qa > 500 mL/min after 1 year of FIR therapy (data
not shown).
We analyzed FIR therapy as a predictor of unassisted
patency, adjusting for age, sex, DM, hypertension, and low
initial Qa (Table 6). FIR therapy tended to improve the 1 year
unassisted patency in multivariable analysis (hazard
ratio ¼ 0.09, P ¼ 0.071). Lin et al [7] reported that the 1-year
change in Qa and unassisted patency in 145 AVF patients
were mean 36.3 ± 166.2 mL/min and 85.9%, respectively. Half
(77 of 145) of the patients have received a PTA previously. Our
1-year change in Qa and unassisted patency in 25 AVF patients
with FIR therapy were mean 137.6 ± 415.1 mL/min and 90%,
respectively. Lai et al [16] reported that FIR therapy after PTA
enhanced unassisted patency at 1 year in arteriovenous graft
(AVG), whereas it had no effect in AVF.
Old age, female, and DM had no effect on the 1 year changes
in Qa (Table 5). Patients with Qa < 500 mL/min at the baseline
and thosewithout hypertension had greater changes of Qa after
1 year. An initial Qa of < 500 mL/min is a known risk factor for
poor primary patency [18]. Robbin et al [19] suggested that 2
risk factors for AVF maturation are a minimumvein diameter ofrol.
Figure 2. Comparison of the 1-year unassisted patency between FIR therapy and control group.
FIR, far-infrared.
Table 5. Linear regression analysis for the 1-year change of access blood ﬂow
Variables Univariable Multivariable
Beta (95% CI) P Beta (95% CI) P
Age (y) e9.18 (e31.50, 13.15) 0.411 e2.85 (e24.01, 18.31) 0.786
Female 288.19 (e190.13, 766.51) 0.230 237.33 (e214.09, 688.74) 0.293
DM 167.12 (e314.24, 648.47) 0.487 265.81 (e181.97, 713.59) 0.236
Hypertension e1,006.45 (e1,762.03, e250.86) 0.010 e567.91 (e1,416.70, 280.87) 0.183
Initial ﬂow < 500 908.99 (398.36, 1,419.62) 0.001 700.45 (93.23, 1,307.67) 0.025
FIR therapy 409.39 (e63.97, 882.74) 0.088 5.46 (e486.12, 497.04) 0.982
Beta means the coefﬁcient of linear regression analysis.
CI, conﬁdence interval; DM, diabetes mellitus; FIR, far-infrared.
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FIR therapy improved physiological maturation (deﬁned as an
AVF diameter of 4 mm and Qa of 500 mL) at 3 months after
AVF creation. In our results, initial Qa of < 500 mL/min did not
inﬂuence the 1-year unassisted patency. If we could improve
Qa at anytime, we can improve the access survival.Table 6. Cox PH regression analysis for the 1-year unassisted patency
Variables Univariable Multivariable
HR (95% CI) P HR (95% CI) P
Age (y) 0.98 (0.93e1.05) 0.619 1 (0.93e1.08) 0.940
Female 2.43 (0.49e12.07) 0.276 3.8 (0.63e22.98) 0.146
DM 2.32 (0.55e9.74) 0.249 5.61 (1.07e29.49) 0.042
Hypertension 0.29 (0.06e1.44) 0.129 0.16 (0.02e1.51) 0.109
Initial
ﬂow < 500
1.32 (0.27e6.53) 0.736 1.87 (0.16e21.25) 0.614
FIR therapy 0.42 (0.08e2.08) 0.288 0.09 (0.01e1.23) 0.071
CI, conﬁdence interval; DM, diabetes mellitus; FIR, far-infrared; HR,
hazard ratio; PH, proportional hazard.Until now, we do not have the deﬁnite therapy for preven-
tion of vascular access failure. The surveillance and pre-emptive
PTA were disappointed in this point. Although systemic man-
agement by agents such as dipyridamole plus aspirin and ﬁsh
oil have been successful, systemic levels of such agents may
expose the patients to signiﬁcant adverse effects [20,21]. Local
therapies were therefore developed. FIR therapy is a peri-
vascular approach, which is appealing given that (1) the
adventitial and medial layers are thought to be the source of
many cells that populate the neointimal hyperplasia and (2)
denudation of the endothelial layer is avoided [22]. FIR therapy
has thermal and nonthermal effects. Upregulation of endo-
thelial nitric oxide synthase is considered to be a thermal effect
[5,23,24]. Decreases in oxidative stress, suppression of inﬂam-
mation, and improved endothelial function [5,20,24e26] have
been suggested to be nonthermal effects. FIR therapy promotes
microvascular angiogenesis, increases skin microcirculation,
and improves skin wound healing [3,26,27]. Future studies
should focus on these mechanisms in humans.
Kidney Res Clin Pract 35 (2016) 35e4140This single-center, clinical study has some limitations. First,
it was not a placebo-controlled study. Since blinding regarding
the intervention was impossible, we could not randomize pa-
tient with FIR therapy and control at initial study design.
Although 25 AVF patients with FIR therapy were prospectively
studied, the control patients were paired for the effect on Qa
and patency after 1-year FIR therapy. Second, the enrolled pa-
tients were not homogeneous. They had varied PTA histories
and comorbidities. The percentage of use of antihypertensive
agents, especially calcium channel blocker, and anticoagulation
agents in the FIR group was greater than that in the control
group. Third, many patients dropped out. If we shorten FIR
therapy during 3 months, our result should be more powerful.
Fourth, there are no data on pain in the control group, and it is
not clear whether the improvement of pain in the study group
can be attributed solely to FIR therapy.
However, this study also has strengths. First, it evaluated the
safety of FIR therapy. Second, it evaluated the effects of FIR
therapy on needling pain. Third, we showed the 1-year effect of
FIR therapy in Qa and patency. Fourth, we suggested a question
about the duration of FIR therapy.
In conclusion, we have demonstrated that FIR therapy im-
proves needling pain. Although FIR therapy improved Qa, FIR
therapy did not improve unassisted 1-year patency compared
with the control. However, more large and multicenter studies
are needed to evaluate the effect of FIR therapy on access sur-
vival in AVF patients.
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